Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877292 · ClinicalTrials.gov registry record
A New Prenatal Blood Test for Down Syndrome
A clinical trial, sponsored by Women and Infants Hospital of Rhode Island.
- Completed
- Registry status
- 4,664
- Enrollment target
NCT00877292 is a clinical trial that has completed, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 4,664 participants.
The verdict
NCT00877292 has completed, sponsored by Women and Infants Hospital of Rhode Island.
- COMPLETED
- Registry status
- 4,664 participants
- Enrollment target
Study Summary
The study will examine the sensitivity and specificity of a circulating cell-free nucleic acid test (DNA/RNA) to identify Down syndrome between about 10 weeks and 21 weeks 6 days gestation. In addition, the new test may be used to identify trisomy 13 and 18 as part of a more complete laboratory developed test. We hypothesize that the new circulating cell-free fetal NA-based test will accurately and precisely measure specific fetal markers in maternal circulation and that measurement will lead to the ability to noninvasively identify with high sensitivity and specificity, fetal chromosome abnormalities, such as Down syndrome.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,664 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877292
The ClinicalTrials.gov registry entry for NCT00877292 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,664 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women and Infants Hospital of Rhode Island, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00877292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00877292 about?
NCT00877292 is a clinical study titled "A New Prenatal Blood Test for Down Syndrome". The study will examine the sensitivity and specificity of a circulating cell-free nucleic acid test (DNA/RNA) to identify Down syndrome between about 10 weeks and 21 weeks 6 days gestation. In addition, the new test may be used to identify trisomy 13 and 18 as part of a more complete laboratory deve...
What is the current status of trial NCT00877292?
This trial is currently completed. The enrollment target is 4,664 participants. The study started on 2009-02. Estimated completion is 2011-05.
Who is sponsoring clinical trial NCT00877292?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.